<DOC>
	<DOCNO>NCT01107535</DOCNO>
	<brief_summary>Published data Organizaci√≥n panamericana de la Salud show Peru 's mortality rate acute respiratory infection ( ARI ) infants less one year life second Haiti ( 14,150/100,000 ) . Government data report show marked increase RSV infection Peru . `` Instituto Nacional de Salud '' ( Peru 's National Institute Health ) report January 1st February 26th 2006 , 62 % positive sample correspond RSV . Epidemiological data Lima-Peru , demonstrate specific season RSV infection although data suggest increase RSV activity cold month ( May September ; INS data ) . Clinical study show give five dos Synagis ( palivizumab ) result serum concentration &gt; 30 ug/mL &gt; 20 week . The aim post-marketing observational study determine RSV hospitalization rate high-risk infant receive Synagis ( palivizumab ) Social Security Hospitals context routine clinical practice .</brief_summary>
	<brief_title>Effectiveness Synagis ( Palivizumab ) Immunoprophylaxis Preterm Infants With High Risk Severe Respiratory Syncytial Virus ( RSV ) Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Palivizumab</mesh_term>
	<criteria>Receiving Synagis ( palivizumab ) immunoprophylaxis respiratory syncytial virus season , accord usual clinical practice : Infants bear &lt; = 32 week gestation younger 6 month age begin respiratory syncytial virus season . Children bronchopulmonary dysplasia receive medical treatment last 6 month , first year life . Children 12 month young hemodynamically significant acyanotic congenital heart disease ( pulmonary hypertension heart failure treatment ) . Major congenital malformation aside congenital heart disease Chronic pulmonary disease bronchopulmonary dysplasia Active infection Contraindication Synagis Receipt another immunoglobulin preparation include restrict polyclonal intravenous immunoglobulin , cytomegalovirus hyperimmunoglobulin ( Cytogam ) , respiratory syncytial virus hyperimmunoglobulin ( Respigam ) . Any condition accord deem obstacle study conduction represent unacceptable risk participate investigator .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>6 Months</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Synagis ( palivizumab ) immunoprophylaxis</keyword>
	<keyword>Respiratory syncytial virus infection</keyword>
	<keyword>Preterm infant</keyword>
</DOC>